PMID- 33106149
OWN - NLM
STAT- MEDLINE
DCOM- 20211025
LR  - 20211025
IS  - 2212-3911 (Electronic)
IS  - 1574-8863 (Linking)
VI  - 16
IP  - 2
DP  - 2021
TI  - Efficacy and Cardiovascular Safety of Meglitinides.
PG  - 207-216
LID - 10.2174/1574886315666201026125848 [doi]
AB  - Meglitinides are a group of oral hypoglycemic medications currently approved for 
      the treatment of type 2 diabetes mellitus (T2DM). Two meglitinide molecules, 
      Repaglinide and Nateglinide, are presently in use. Repaglinide is preferred 
      because of its superior glycemic efficacy. They have modest efficacy with a mean 
      decrement of glycosylated haemoglobin (HbA1c) ranging between -0.2 to -1.50% with 
      individual therapy. Additional HbA1c reduction can occur with combination therapy 
      with other oral hypoglycemics. This class of drugs is effective in controlling 
      postprandial hyperglycemia with minimal risk of hypoglycemia. It is also useful 
      in patients with variable meal timings, especially in the elderly, and in 
      patients with renal failure. There are a dearth of long-term studies on 
      meglitinides to assess cardiovascular outcomes or mortality in T2DM, although the 
      Nateglinide and Valsartan in Impaired Glucose ToleranceOutcomes Research 
      (NAVIGATOR) study showed no difference between Nateglinide and placebo with 
      regard to the core composite cardiovascular outcomes. Based on a PubMed 
      literature search using key words: 'meglitinides', 'repaglinide', 'nateglinide', 
      'HbA1c', 'glycated haemoglobin', 'cardiovascular safety', 'cardiovascular 
      events', 'cardiovascular outcome trials', 'type 2 diabetes mellitus' and heart 
      failure, and combining the search terms using Boolean operators 'AND', 'OR' and 
      'NOT' as needed we compiled current evidence for use of these oral hypoglycemic 
      agents in clinical use. This article is an attempt to review the efficacy and 
      cardiovascular (CV) safety of Meglitinides to help clinicians to use this class 
      of oral hypoglycaemic agents prudently.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Philip, Jim
AU  - Philip J
AD  - Department of Endocrinology & Metabolism, NMC Speciality Hospital, Al Ain, 
      United Arab Emirates.
FAU - Fernandez, Cornelius James
AU  - Fernandez CJ
AD  - Department of Endocrinology & Metabolism, Pilgrim Hospital, PE21 9QS, Boston, 
      United Kingdom.
LA  - eng
PT  - Journal Article
PL  - United Arab Emirates
TA  - Curr Drug Saf
JT  - Current drug safety
JID - 101270895
RN  - 0 (Benzamides)
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
RN  - 41X3PWK4O2 (Nateglinide)
RN  - 8V6OK1I088 (meglitinide)
SB  - IM
MH  - Aged
MH  - Benzamides
MH  - Blood Glucose
MH  - *Diabetes Mellitus, Type 2/diagnosis/drug therapy
MH  - Humans
MH  - Hypoglycemic Agents/adverse effects
MH  - Nateglinide
OTO - NOTNLM
OT  - Meglitinides
OT  - cardiovascular outcome trial (CVOT)
OT  - heart failure
OT  - nateglinide
OT  - repaglinide
OT  - type 2 diabetes mellitus (T2DM)
EDAT- 2020/10/28 06:00
MHDA- 2021/10/26 06:00
CRDT- 2020/10/27 05:35
PHST- 2020/05/13 00:00 [received]
PHST- 2020/07/01 00:00 [revised]
PHST- 2020/08/08 00:00 [accepted]
PHST- 2020/10/28 06:00 [pubmed]
PHST- 2021/10/26 06:00 [medline]
PHST- 2020/10/27 05:35 [entrez]
AID - CDS-EPUB-110903 [pii]
AID - 10.2174/1574886315666201026125848 [doi]
PST - ppublish
SO  - Curr Drug Saf. 2021;16(2):207-216. doi: 10.2174/1574886315666201026125848.